Lord Darzi’s undeclared interests in four companies included $500,000 of shares in US-based healthcare venture
Last modified on Wed 19 Mar 2025 06.02 EDT
The independent peer Lord Darzi, a senior adviser to the government on the NHS , failed to officially declare shareholdings in healthcare companies worth hundreds of thousands of pounds. Ara Darzi is an eminent surgeon and professor at Imperial College London whose report on the NHS for the government in September informed the decision announced last week by the health secretary, Wes Streeting, to abolish NHS England . Darzi also has an extensive portfolio of private interests in commercial medical companies. A Guardian investigation has found Darzi held shares and share options in four healthcare companies that he did not declare on his House of Lords register of interests. The information was missing from the register when Streeting appointed him to lead the investigation into the state of the health service. Lawyers for Darzi said the omission was an “oversight”, and that some of the information had been publicly available in US stock market filings. They said he had written to the registrar of Lords interests to request his entry be corrected. The undeclared interests include $500,000 of shares and $800,000 of share options in Evelo Biosciences, a US-based healthcare venture where Darzi was a director. The shares were bought in 2022 and Darzi held them until June 2023, according to his now corrected register . Darzi’s lawyers said he had never obtained benefit from the share options as he never converted them into shares. The Lords rules require peers, as lifelong members of the UK parliament, to be transparent about their commercial interests. Until September 2023, all shares or share options worth more than £50,000 were declarable. The threshold then rose to £100,000. Darzi’s share options in Evelo were above the registrable value for five years, from the start of his directorship in 2018, when his first remuneration package was $27,438 in fees, and $458,202 in share options, to June 2023 when he says his interest ended. Darzi resigned from the Evelo board in 2022, and the company went into liquidation last year. Evelo was a start-up backed by a US venture capital group, Flagship Pioneering, where Darzi has a paid role as chair of the “health security initiative” of its UK arm. Flagship was an early backer of Moderna, which became a multibillion-dollar company after its Covid vaccine sold around the world. Darzi declares on the register that he is a director at three other companies backed by Flagship: Montai Health Inc, a molecular nutrition company; Harbinger Health, focusing on early cancer detection; and YourBio Health Inc, which has created a blood testing device that can be sold direct to the public. Unlike Evelo, these companies are not listed on any stock market, which means details about shareholders are not publicly available. Asked whether he had a financial interest in the three companies, lawyers for Darzi said he did. They said he held share options in all three companies above the £100,000 registrable value, and a holding of shares in Montai Health Inc since January 2022, also above the value requiring them to be registered. Share options give the holder the right to buy shares at a fixed price, and are usually converted into shares by the holder when their value rises above the fixed price. Dr Jonathan Rose, a political integrity expert at De Montfort University, said: “Breaches of the rules are corrosive to the trust that the public should be able to have in parliament. Given that the House of Lords specifically wants people with outside interests to use their knowledge for the public good, and given that people are appointed for life and can’t be removed by elections, it is critical that the rules are followed in full.”
Darzi was appointed to the Lords and made a junior health minister by Gordon Brown in 2007. He led a review of the NHS for the Labour government at that time. Darzi was a non-executive director of NHS England from 2020 to 2022 , and he currently chairs the NHS Accelerated Access Collaborative (AAC), which negotiates deals with healthcare and life science businesses. His “rapid investigation” into the NHS for Streeting produced a report in September that found the NHS to be in “serious trouble”, and was highly critical of the Conservative government’s years of austerity and the 2012 reorganisation which produced NHS England. The report recommended a series of changes, including a “major tilt towards technology”, saying: “There is enormous potential … for life sciences breakthroughs to create new treatments.”
Darzi’s lawyers told the Guardian the AAC role was explicitly a collaboration between the NHS and the life sciences industry, and he did not have a conflict of interest between his public roles and his directorships and share interests in private healthcare businesses. They disclosed he took a “leave of absence” from his paid role at Flagship Pioneering while he led the NHS review. They said: “Before accepting the appointment … our client disclosed his personal interests to [Streeting] (by sharing his House of Lords register of interests) and took a leave of absence from his position at Flagship while he was undertaking the NHS investigation and was not paid during this time. This was entirely at our client’s own behest and specifically to ensure that there could be no perceived conflict of interest.”
A Department of Health and Social Care spokesperson said: “Lord Darzi is a world-renowned cancer surgeon who has dedicated more than three decades of his life to the NHS and medical innovation. “All relevant due diligence processes were followed.”
Darzi’s lawyers said he had not realised peers were required to register share options, and that his failure to do so was “an oversight”. He acknowledged that he should have declared them, and his shareholding in Montai. “Lord Darzi has devoted his life to the advancement of medicine and scientific discovery, and over the course of this he has worked both with government and industry to improve the health system and support the life sciences sectors in this country. He has gone to great lengths to ensure that there have not been conflicts of interests, perceived or otherwise,” the lawyers said. “It has recently been brought to Lord Darzi’s attention that the share options he was granted as part of his role as director of Evelo, Montai Therapeutics, Harbinger Health and YourBio Health and his subsequent personal investment to support Evelo and Montai Therapeutics’s scientific research exceeded the reportable threshold for the House of Lords register. He has acted immediately to rectify this oversight and update the entry on the register. Lord Darzi is very grateful to the Guardian for helping bring this oversight to light.”
Explore more on these topics

Peer who led government NHS review failed to declare shares in health firms

News provided by
Share this article
Share toX
Data underscore Harbinger's data science capabilities that power early-stage multi-cancer detection technology and advance the platform's ability to provide multiple dimensions in clinical informativeness
CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Harbinger Health ("Harbinger," "the Company"), a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, today announced the presentation of four abstracts at clinical and scientific meetings for cancer research and data science. Three abstracts were presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation in San Diego, California from November 13-16, 2024, and an additional abstract was presented at the Cold Spring Harbor Laboratory Biological Data Science meeting in Cold Spring Harbor, New York from November 13-16, 2024. "The results presented across these four studies underscore the power of our computational platform to tackle some of the most significant computational challenges in early cancer screening, including data limitations in critical cohorts, signal complexity, and model accuracy," said Kieran Chacko, Executive Vice President of Data Science and Strategy at Harbinger Health. "Our platform's capabilities are enabling us to generate precise, disease-specific insights that could provide doctors and patients with critical information on early-stage disease, tissue of origin, and disease severity – helping deliver performance and clinical informativeness to blood-based cancer detection." Chacko continued, "Our computational platform is pioneering new frontiers in cancer detection by integrating advanced machine learning capabilities with foundational cancer biology. We developed transfer learning methods to map high-signal cancer tissue data to low-signal cfDNA, achieving highly accurate tissue of origin predictions. Additionally, we built a biology-guided deep neural network designed to interrogate and learn cancer methylation patterns at the single fragment level, significantly improving early-stage sensitivity. Finally, by using data augmentation approaches to generate high-fidelity cfDNA training datasets, we are overcoming challenges like limited data and signal heterogeneity, enabling our platform to isolate tumor signals with unmatched precision and opening pathways for broader applications across the cancer care continuum." The following abstracts were presented at AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation:
A large-scale data simulation platform isolates tumor signal from cell-free DNA (cfDNA) and improves tissue of origin prediction accuracy (B065)
Harbinger developed capabilities to generate diverse, large-scale, high-fidelity simulated cell-free DNA (cfDNA) datasets for robust and accurate machine learning (ML) model development. Specifically, the platform technology addresses challenges like limited data availability, heterogeneous low-signal cfDNA, and confounding technical and biological biases. Supplementing tissue of origin (TOO) models with a curated simulated dataset resulting in a 10%-point increase in balanced accuracy across 10 groups of cancer types. A key advantage of the platform is its ability to enhance ML models by matching confounding variables within training data, such as age or target coverage. The platform is adaptable to other diseases and biofluids, enabling potential expansion to additional diagnostic and screening applications. Transfer learning for accurate tissue of origin classification from cfDNA methylation (PR019, B055)
Harbinger developed a transfer learning method that leverages methylation signatures learned from cancer tissue biopsy samples to predict the TOO of clinical cancer cfDNA samples. This method overcomes major challenges of developing robust and generalizable TOO models, including insufficient cancer type-specific training data and technical confounders in low-signal cfDNA. The method utilizes the high methylation signal in cancer tissue biopsies for feature extraction and adapts it to plasma cfDNA data for accurate TOO classification. The proposed model achieved 89% balanced accuracy in classifying the TOO across 10 groups of cancer types, and outperformed models trained solely on plasma cfDNA data. This approach demonstrates the potential for scalable, automated feature extraction from signal-rich tissue biopsy data for TOO and could potentially extend capabilities to rarer cancer types and further disease sub-stratification. Liquid biopsy-based detection of triple negative breast cancer using DNA methylation biomarkers (A053)
Harbinger investigated whether a blood-based test could provide a non-invasive, sensitive method for detecting early triple-negative breast cancer (TNBC), aiming to overcome the constraints of conventional imaging techniques. Specific methylation biomarkers distinguishing TNBC were identified, and a feed-forward neural network classifier was developed that applied transfer learning and these biomarkers to learn methylation signatures in cancer tissue biopsy samples and map them to cfDNA. Harbinger's platform accurately distinguished TNBC from non-TNBC using a binary classifier, achieving 84% accuracy in cfDNA samples. These results demonstrate the platform's ability to identify high-risk, aggressive disease with a blood-based methylation test, offering insights into cancer severity and potentially reducing over-treatment and over-diagnosis. Additionally, Harbinger presented the following abstract at the Cold Spring Harbor Biological Data Science Meeting:
Extracting tumor signal from cell-free DNA using deep neural networks improves early cancer detection
Harbinger designed a novel deep-learning framework to detect cancer methylation signal at the single-DNA-fragment resolution to improve early-stage sensitivity where the signal is weakest. This capability was enabled by Harbinger's simulated data platform, through which billions of simulated samples were generated for model training. Classifiers trained on feature vectors extracted using this framework improved overall sensitivity by 12.8% points at 98% specificity, compared to a standard benchmark classifier trained on summary methylation statistics. Improvements to early-stage sensitivity were observed across multiple cancer types, and classifier scores showed lower correlation with biological (e.g., age) and technical variables (e.g., bisulfite conversion efficiency). These results, combined with the model's training efficiency, highlight the transformative potential of models developed for fragment-level resolution data in early-stage cancer detection. About Harbinger Health
Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test. Harbinger envisions a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies. Harbinger was founded by Flagship Pioneering after three years of foundational research in its Labs unit and launched in 2020. Learn more about Harbinger by visiting  Harbinger-Health.com  or following us on X  (@harbingerhlth ) and  LinkedIn . Media Contact:

Harbinger Health Presents Data Demonstrating Novel Capabilities of its Computational Platform to Enhance Performance and Clinical Informativeness in Blood-based Early Cancer Detection

News provided by
Share this article
Share toX
Novel techniques and methods leverage Harbinger's proprietary biomarkers and aim to deliver low-cost and highly accurate tools for cancer screening, detection and diagnosis
CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Harbinger Health, a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, today announced the presentation of three abstracts showcasing multiple product innovations within its platform for blood-based early cancer detection. Two abstracts were presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation in San Diego, California, from November 13-16, 2024. These data demonstrate significant advances in the ability of the company's blood-based cancer detection technology to detect low levels of circulating tumor DNA (ctDNA) in early-stage disease, potentially enabling more cost-effective and broadly accessible early cancer screening. An additional abstract will be presented at the Association for Molecular Pathology (AMP) 2024 Annual Meeting in Vancouver, British Columbia, Canada, from November 19-23, 2024. These data will highlight the capabilities of Harbinger's proprietary biomarkers to identify advanced adenomas, which are precursor lesions that confer an increased risk for colorectal cancer development. "Taken together, these data demonstrate that Harbinger's biological, technological and methodological innovations could offer more accurate, accessible and clinically informative options for early disease detection and progression monitoring," said Tony Shuber, Chief Innovation Officer at Harbinger Health. "These product innovations complement the tremendous advances of our data science team. Holistically, with every step forward we take, we are getting closer towards our ultimate goal of creating tests that can integrate seamlessly into current and future care paradigms." The following abstracts were presented at AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation:
A Real-time PCR Method for the Detection of Cancer-specific Methylation Patterns in cfDNA (Poster #A014)
Non-invasive liquid biopsies that leverage methylation as a biomarker for ctDNA need to be sensitive to detect low-level tumor-specific methylation patterns. Harbinger's quantitative methylation-specific PCR (qMSP) with locked nucleic acid (LNA) blockers targets contiguous CpG sites. The LNA blockers prevent non-specific amplification, enabling detection of low abundance hypermethylated DNA fragments down to 23 copies. When applied to ten pan-cancer methylation loci, the qMSP-LNA assay effectively distinguished cancer from non-cancer cfDNA with high specificity, even at low ctDNA levels. This cost-effective method could expand access to early cancer detection and monitoring, with high sensitivity for clinically relevant methylation signals. A Methylation State Specific Targeted Background Depletion Technique for Enrichment of ctDNA Fraction (Poster #A035)
Liquid biopsies are promising in cancer diagnostics, but low levels of ctDNA make detection challenging. Harbinger developed a novel CRISPR/Cas12a-based method depleting unmethylated CpG sites at precise locations, in non-cancerous cfDNA. The remaining DNA is enriched for methylated, ctDNA molecules. This method achieved an average of nine-fold increase in methylation signal down to a 0.01% fraction of methylated DNA. This technique improves the signal-to-noise ratio in methylation bioassays, enabling enhanced ctDNA detection in clinical settings. Additionally, Harbinger presented the following abstract at the AMP 2024 Annual Meeting:
Detection of Precancerous Colorectal Polyps Using a Highly Sensitive Multi-Cancer Blood-Based Assay (ST088)
Harbinger's blood-based cfDNA assay, known as HHx, demonstrated 38% sensitivity (8 out of 21) in detecting advanced adenomas at 90% specificity, including cases with and without high-grade dysplasia. The company's proprietary biomarkers were detectable in precancer tissue and remained detectable within the cfDNA milieu – demonstrating HHx's sensitivity to low abundance signals characteristic of precancerous lesions. Analysis of cfDNA tumor fraction demonstrated a progressive increase in cancer signals from non-cancer individuals (0.0186%), to advanced adenoma cases (0.0289%), and to colorectal cancer cases (ranging from 0.05% to 4.2% for stage I to stage IV, respectively). By identifying precancerous polyps with high specificity, Harbinger's biomarkers have been leveraged to identify clinically relevant patients with limited tumor signal. The presence of these biomarkers from precancerous lesions through advanced-stage disease speaks to their universal nature in cancer detection. The results validate the biology underpinning Harbinger's platform and support the potential clinical utility of this technology as a complementary screening tool that could enhance current cancer detection strategies. About Harbinger Health
Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test. Harbinger envisions a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies. Harbinger was founded by Flagship Pioneering after three years of foundational research in its Labs unit and launched in 2020. Learn more about Harbinger by visiting  Harbinger-Health.com  or following us on X  (@harbingerhlth ) and  LinkedIn . MEDIA CONTACT:

09:00 ET
			
			
				Harbinger Health Announces Data Showcasing Product Innovations of Its Blood-based Platform for Early Cancer...

Harbinger Health partners with New York clinic on cancer blood trials
The deal between the two is set to advance the company’s blood test before rolling it out across more indications. Share
The deal between the two means that Harbinger will leverage MSK’s cancer centre and academic institution to validate the company’s assay. Credit: Shutterstock / JHVEPhoto
Massachusetts-based company, Harbinger Health has struck a partnership with New York hospital, Memorial Sloan Kettering Cancer Center (MSK), to advance a blood-based early cancer detection platform validating a prospective clinical study. The deal between the two means that Harbinger will leverage MSK’s cancer centre and academic institution to validate the company’s assay from its Cancer Origin Epigenetics-Harbinger Health (CORE-HH, NCT05435066) prospective clinical study, in hopes of proving the test to be accessible and clinically informative. Go deeper with GlobalData
The study is similarly running alongside another clinical study carried out at Tennessee Sarah Cannon Research Institute (SCRI) consisting of 10,000 participants for a clinical trial similarly aimed at validating the company’s blood cancer test. Interim chief medical officer for Harbinger Health, Hutan Ashrafian said: “We are pleased to collaborate with MSK’s renowned team to tap into their state-of-the-art research capabilities and the exceptional diversity of patients with cancer they treat every day. “MSK will play a critical role in turbocharging our data collection efforts and opening new research directions in the development of affordable, accessible, and clinically informative early cancer detection tests for all patients. Together, we are working towards world-class early cancer detection that could transform the way cancer is diagnosed and managed on a societal level.”
Results from the dual CORE HH study will be used in part of a comprehensive validation program for Harbinger’s two-tier, multi-cancer blood test with the company aiming to extend validation to patients with a broader range of tumor types as well as enhance the next generation of diagnostic tests. How well do you really know your competitors? Access the most comprehensive Company Profiles            on the market, powered by GlobalData. Save hours of research. Gain competitive edge. Not ready to buy yet? Download a free sample
We are confident about the                        unique                        quality of our Company Profiles. However, we want you to make the most                        beneficial                        decision for your business, so we offer a free sample that you can download by                        submitting the below form
By GlobalData
Submit
Tick here to opt out of curated industry news, reports, and event updates from Medical Device Network. Submit and                                    download
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. The announcement comes more than a year after the company was able to secure $140m in a Series B funding round to complete the Cancer ORigin Epigenetics-Harbinger Health clinical study of one of its cancer screening platforms, HarbingerHx. Lead investigator in the New York study, Luke Pike, said: “Developing a deeper understanding of early cancer detection using blood tests is an important area of research for us at MSK as we continuously explore ways to improve the care we provide our patients. “Harbinger’s test is compelling for its basis in the biology in the origins of cancer, an insight that has long been known in the cancer field but inaccessible to date as a means of detection. This effort reflects our shared commitment to advancing technology in ways that will benefit patients and healthcare systems alike. We look forward to seeing the impact this collaboration will have in the years to come.”
Elsewhere in the field of cancer diagnostics, the US Food and Drug Administration (FDA) has approved Caris Life Sciences’s MI Cancer Seek as a companion diagnostic to multiple cancer drugs across six cancer indications. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

Harbinger Health partners with New York clinic on cancer blood trials

News provided by
Share this article
Share toX
Collaboration to include future projects developing novel tools for cancer screening and detection that leverage premier academic institution's large set of diverse cancer samples
CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Harbinger Health ("Harbinger," "the Company"), a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, today announced a new collaboration with Memorial Sloan Kettering Cancer Center  ("MSK"), one of the world's largest leading cancer centers, to advance the Company's blood-based early cancer detection platform. In the near-term, Harbinger will leverage MSK's expertise as a premier cancer center and academic institution to validate the Company's assay from its Cancer Origin Epigenetics-Harbinger Health ( CORE-HH , NCT05435066) prospective clinical study and advance its mission of developing an affordable, accessible and clinically informative test. This parallel study will complement Harbinger's ongoing work with the Sarah Cannon Research Institute  and will focus on a large sample of cancers. Pike, M.D., D.Phil., Director of Brain Radiation Oncology at MSK, and MCED Lead for the institution's Global Biomarker Development Program, will serve as lead investigator and assume the role of co-chair for the Sarah Cannon study. In the long term, Harbinger and MSK aim to extend validation to patients with a broader range of tumor types, enhance the next generation of diagnostic tests, and collaborate on real-world studies for evidence generation to support future regulatory submissions. This collaboration is part of Harbinger's long-term strategy to build a diverse recruitment base – encompassing both ethnic diversity and a wide variety of cancer types – while continuously refining, enhancing, and validating its technology. "We are pleased to collaborate with MSK's renowned team to tap into their state-of-the-art research capabilities and the exceptional diversity of patients with cancer they treat every day," shared interim Chief Medical Officer Hutan Ashrafian, M.D., Ph.D., M.B.A. "MSK will play a critical role in turbocharging our data collection efforts and opening new research directions in the development of affordable, accessible and clinically informative early cancer detection tests for all patients. Together, we are working towards world-class early cancer detection that could transform the way cancer is diagnosed and managed on a societal level." "Developing a deeper understanding of early cancer detection using blood tests is an important area of research for us at MSK as we continuously explore ways to improve the care we provide our patients," said Dr. Pike. "Harbinger's test is compelling for its basis in the biology in the origins of cancer, an insight that has long been known in the cancer field but inaccessible to date as a means of detection. This effort reflects our shared commitment to advancing technology in ways that will benefit patients and healthcare systems alike. We look forward to seeing the impact this collaboration will have in the years to come." As the CORE-HH study progresses, the collaboration with MSK will serve as a common platform for data recruitment and transformation, building a comprehensive validation program for Harbinger's two-tier, multi-cancer blood test. This will contribute significantly towards Harbinger's commercialization strategy, adding value to the company's evidence base and positioning it for long-term success. About Harbinger Health
Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing low-cost, multi-cancer blood tests. Harbinger envisions a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies. Harbinger was founded by Flagship Pioneering after three years of foundational research in its Labs unit and launched in 2020. Learn more about Harbinger by visiting www.harbinger-health.com  or following us on Twitter (@harbingerhlth ) and LinkedIn . Media Contact

09:00 ET
			
			
				Harbinger Health Announces New Partnership with Leading Cancer Center to Accelerate Clinical Evidence Gener...

Memorial Sloan Kettering Cancer Center is an institution in the healthcare sector that focuses on cancer treatment, research, and education. The center offers services including personalized patient care, clinical trials, and cancer research aimed at improving prevention, diagnosis, and treatment. MSK also provides education and training for healthcare professionals through various graduate and continuing medical education programs. It was founded in 1884 and is based in New York, New York.

Memorial Sloan Kettering Cancer Center

Massachusetts-based company , Harbinger Health has struck a partnership with New York hospital , Memorial Sloan Kettering Cancer Center , to advance a blood-based early cancer detection platform validating a prospective clinical study .

Flagship Pioneering is a biotechnology company involved in creating platform companies within the biotechnology sector. The company provides services and products related to genetic medicine capabilities. Flagship Pioneering serves sectors that need healthcare solutions and sustainable practices. It was founded in 2000 and is based in Cambridge, Massachusetts.

Flagship Pioneering

The next big cancer tech acquisition could be one of these 5 liquid biopsy players

The Digital Health 50: The most promising digital health companies of 2023

The oncology tech market map

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Digital Health

This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery. 

Oncology Tech

Digital Health 50

Artificial Intelligence

Series A

Series B

Harbinger Health focuses on fundamentally transforming cancer care through early detection and prevention within the healthcare sector. The company offers blood-based tests that enable the detection of cancer in its earliest stages, utilizing artificial intelligence and insights into cancer biology to identify pre-disease states. Harbinger Health's solutions aim to make cancer screening accessible and affordable, contributing to a proactive approach in cancer care. It was founded in 2018 and is based in Cambridge, Massachusetts.

DH50 list - Companies

Harbinger Health

Catalyst

M&G Investments

Partners Investment

Pictet Group

Undisclosed Investors

GRAIL is a healthcare company focused on the early detection of cancer and precision oncology. The company main offerings include the Galleri test, a multi-cancer early detection test that screens for various cancers using blood samples by analyzing DNA methylation patterns with machine learning algorithms. GRAIL was formerly known as PSC15. It was founded in 2016 and is based in Menlo Park, California.

GRAIL

QIAGEN provides sample-to-insight solutions within the molecular diagnostics and life sciences sectors. The company supplies technologies for isolating and processing DNA, RNA, and proteins, along with assay technologies for analysis, bioinformatics software for data interpretation, and automation solutions for laboratory workflows. QIAGEN's products cater to customers in human healthcare, academia, pharmaceutical R&D, industrial applications, and forensics. It was formerly known as Diagen. It was founded in 1984 and is based in Hilden, Germany.

QIAGEN

Natera specializes in cell-free deoxyribonucleic acid (DNA) testing, focusing on insights for oncology, women's health, and organ health within the healthcare sector. The company offers noninvasive genetic tests that assist in early disease detection, transplant health assessment, and hereditary condition identification. Natera's tests measure fetal, tumor, or donor cfDNA at the molecular level. Natera was formerly known as Gene Security Network. It was founded in 2004 and is based in Austin, Texas.

Natera

Freenome focuses on early cancer detection through blood tests. The company's main offerings include next-generation blood tests that utilize multiomics technology and machine learning to identify cancer in its early stages. Freenome primarily serves the healthcare sector with a focus on improving cancer screening and detection. It was founded in 2014 and is based in Brisbane, California.

Freenome

Veracyte (NASDAQ: VCYT) is a global diagnostics company that focuses on providing insights for cancer diagnosis and treatment. The company offers a suite of molecular tests and genomic classifiers designed to assist clinicians in making informed decisions, thereby helping patients avoid unnecessary procedures and receive timely treatment. Veracyte's products are utilized across various sectors of the healthcare industry, including oncology and personalized medicine. It was founded in 2008 and is based in South San Francisco, California.

Veracyte

Universal DX is a company that develops blood-based diagnostics for cancer detection in the healthcare sector. The company creates tests that aim to identify cancer using a proprietary platform that incorporates multi-omics, computational biology, and machine learning to analyze blood samples. Universal DX serves the medical diagnostics industry. It was founded in 2012 and is based in Seville, Spain.

Universal DX

Epic Sciences focuses on advancing the treatment and management of cancer through novel diagnostics within the healthcare sector. The company offers a comprehensive cancer profiling platform that utilizes a liquid biopsy to detect genetic and molecular changes in cancer, providing insights for clinicians and drug development professionals. Epic Sciences' main services include the detection and characterization of rare cells such as circulating tumor cells (CTCs), ctDNA gene panel testing, and immune-cell analysis, which aid in personalizing treatment and monitoring drug resistance. It was founded in 2008 and is based in San Diego, California.

Epic Sciences

Guardant Health is a medicine company that operates in the oncology sector. The company offers blood tests that assist in early detection, treatment monitoring, and decision-making in cancer care. Guardant Health serves patients, healthcare providers, and biopharmaceutical companies. It was founded in 2012 and is based in Redwood City, California.

Guardant Health

Singlera Genomics specializes in the development of liquid biopsy technologies for early cancer detection within the biotechnology sector. The company offers analysis reagents and software designed to determine methylation haplotypes in cell-free DNA, with assays capable of detecting cancer significantly earlier than traditional methods. Singlera's products provide cancer diagnostics through non-invasive testing and advanced bioinformatics. It was founded in 2014 and is based in Yangzhou, China.

Singlera Genomics

NeoGenomics Laboratories operates in precision oncology testing within the healthcare sector, focusing on cancer diagnostics and treatment support. The company provides molecular and genetic testing, next-generation sequencing, and informatics solutions for cancer diagnosis and treatment. NeoGenomics serves pathologists, oncologists, academic centers, and pharmaceutical clients. It was founded in 2001 and is based in Fort Myers, Florida.

NeoGenomics Laboratories

Exact Sciences (EXAS) focuses on the eradication of cancer through the development of diagnostic tests. It operates within the healthcare and biotechnology. It offers a range of tests aimed at preventing cancer, detecting it at an early stage, and guiding its successful treatment. It tests are primarily used in the healthcare industry for cancer diagnosis and treatment. It was founded in 1995 and is based in Madison, Wisconsin.

Exact Sciences

Personal Genome Diagnostics (PGDx) develops tests for cancer at the genomic level, which incorporate sequencing algorithms to find alterations in genomes associated with cancer. The company is developing tests of both tissue samples and blood, the latter of which is known as "liquid biopsy." It is based in Baltimore, Maryland. 

On December 23rd, 2021, Personal Genome Diagnostics was acquired by LabCorp at a valuation between $450M and $575M.

Personal Genome Diagnostics

Delfi Diagnostics focuses on early cancer detection, operating in the healthcare and biotechnology sectors. The company's main service involves the use of novel machine-learning algorithms to analyze fragments of cell-free deoxyribonucleic acid (DNA), which allows for the accurate detection of cancer from a single blood sample. It primarily serves the healthcare industry. It was founded in 2019 and is based in Palo Alto, California.

Delfi Diagnostics

Caris Life Sciences provides molecular profiling services, including DNA and RNA sequencing, to supply oncologists with information about cancer at the molecular level, facilitating personalized treatment plans. The company also offers biopharmaceutical solutions, assisting in the discovery, clinical development, and commercialization of new cancer therapies. It was founded in 2008 and is based in Irving, Texas.

Caris Life Sciences

The liquid biopsy cancer screening market offers a non-invasive alternative to traditional tissue biopsies for detecting cancer. This market includes various solutions such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) tests, which can detect cancer at an early stage and monitor treatment effectiveness. The liquid biopsy method is less invasive, faster, and more cost-effective than traditional biopsies. Additionally, liquid biopsy tests can be used for a range of cancers, including lung, breast, colorectal, and prostate cancer. As the demand for personalized medicine and targeted therapies increases, the liquid biopsy cancer screening market is expected to grow significantly in the coming years.

Name	Work History	Title	Status
Stephen Hahn		Chief Executive Officer	Current
Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more

Name	Stephen Hahn	Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Work History		Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Title	Chief Executive Officer	Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more
Status	Current	Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more

How VCs Use CB Insights

Professional Services

Platform Overview

Harbinger Health

Executives

Harbinger Health Management Team

14 Team Members